key: cord-0746895-49vx2gzj
authors: Ng, Jun Jie; Choong, Andrew M.T.L.
title: Thromboembolic Events in Patients with SARS-CoV-2
date: 2020-04-30
journal: J Vasc Surg
DOI: 10.1016/j.jvs.2020.04.488
sha: 8e34cff90d3c82dcb6e923777c2d26545c4aca9c
doc_id: 746895
cord_uid: 49vx2gzj

nan

Many physicians treating patients with SARS-CoV-2 have noticed an increased 2 incidence of thromboembolic events such as line thrombosis, deep venous thrombosis and 3 pulmonary embolism. Anecdotal as it seems, the increasing chatter and concern about an 4 increased thromboembolic risk in these cannot be ignored. Current evidence is circumstantial 5 at best but portrays a picture of a hypercoagulable state in these patients. Published large 6 observational studies that described clinical characteristics and outcomes of patients with second study is an observational study from the Netherlands that examined the incidence of intensive care unit patients that reported the incidence of venous thromboembolism to be 20 9.9% 3 .

Several studies have also suggested that patients with SARS-CoV-2 may have a 22 hypercoagulable state that could predispose to thromboembolic events. A case series from 23 Singapore reported clot wave analysis parameters that were consistent with 24 hypercoagulability in critically ill patients with SARS-CoV-2 4 . A retrospective study from 25 China found that patients who received anticoagulation seemed to have a better prognosis, 1 especially if they had a higher plasma D-dimer concentration 5 . Lastly, a case series from the 2 United States of America described the successful use of intravenous tissue plasminogen 3 activator for the treatment of acute respiratory distress syndrome in three patients that did not 4 respond to conventional treatment 6 . The results of the case series suggests that pulmonary 5 microvascular thrombosis may be the responsible to the high mortality rate in SARS-CoV-2 6 patients with acute respiratory distress syndrome. The theory regarding pulmonary 7 microvascular thrombosis can be further corroborated by a Chinese study that performed 8 post-mortem examination on patients who died of SARS-CoV-2. They reported that 9 thrombosis was commonly found in small vessels, lungs, and even some extra-pulmonary 10 organs 7.

Although these studies cannot prove that the hypercoagulable state is a direct 12 causative effect of SARS-CoV-2 infection, it is apparent that SARS-CoV-2 patients may 13 have a predilection to thromboembolic events. As such, the International Society on 14 Thrombosis and Haemostasis has recommended that all patients with SARS-CoV-2 infection, 15 including those that are not critically ill, should receive prophylactic dose low molecular 16 weight heparin unless contraindicated 8 . Some institutions are also considering systemic 17 anticoagulation for SARS-CoV-2 patients with high D-dimer levels. This is a serious problem 18 that cannot be overlooked. We strongly urge the medical community to report their 19 experience with thromboembolic events in SARS-CoV-2 patients. 

Prevalence of venous thromboembolism in patients with 3 severe novel coronavirus pneumonia

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Adjunctive Intermittent Pneumatic 9 Compression for Venous Thromboprophylaxis

Infected Patients Exhibit Increased Clot Waveform Analysis Parameters Consistent with 12

Anticoagulant treatment is associated with 14 decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Tissue Plasminogen Activator (tPA) Treatment 17 for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series

Comparison of clinical and pathological features between 20 severe acute respiratory syndrome and coronavirus disease

ISTH interim 23 guidance on recognition and management of coagulopathy in COVID 19